|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A potent PGK1 antagonist reveals PGK1 regulates the production of IL-1βand IL-6显示文摘Glycolytic metabolism enzymes have been implicated in the immunometabolism field through changes in metabolic status. PGK1 is a catalytic enzyme in the glycolytic pathway. Here, we set up a high-throughput screen platform to identify PGK1 inhibitors. DC-PGKI is an ATPcompetitive inhibitor of PGK1 with an affinity of Kd= 99.08 nmol/L. DC-PGKI stabilizes PGK1in vitro and in vivo, and suppresses both glycolytic activity and the kinase function of PGK1. In addition,DC-PGKI unveils that PGK1 regulates production of IL-1β and IL-6 in LPS-stimulated macrophages.Mechanistically, inhibition of PGK1 with DC-PGKI results in NRF2(nuclear factor-erythroid factor 2-related factor 2, NFE2L2) accumulation, then NRF2 translocates to the nucleus and binds to the proximity region of Il-1β and Il-6 genes, and inhibits LPS-induced expression of these genes. DC-PGKI ameliorates colitis in the dextran sulfate sodium(DSS)-induced colitis mouse model. These data support PGK1 as a regulator of macrophages and suggest potential utility of PGK1 inhibitors in the treatment of inflammatory bowel disease. | Liping Liao Wenzhen Dang Tingting Lin Jinghua Yu Tonghai Liu Wen Li Senhao Xiao Lei Feng Jing Huang Rong Fu Jiacheng Li Liping Liu Mingchen Wang Hongru Tao Hualiang Jiang Kaixian Chen Xingxing Diao Bing Zhou Xiaoyan Shen Cheng Luo | 2022 | Acta Pharmaceutica Sinica B2022，12，11： | 2 |
| 2 | Blood compatibility of thermoplastic polyurethane membrane immobilized with water-soluble chitosan/dextransulfate显示文摘 | Lin Wenching Yu Daguang Yang Mingchen | 2005 | Colloids and Surfaces B: Biointerfaces2005，44，： | 1 |
| 3 | Blood compatibility of thermoplastic polyurethane membrane immobilized with water-soluble chitosan/dextran sulfate显示文摘 | Lin Wenching Yu Daguang Yang Mingchen | 2005 | Colloids and Surfaces B: Biointerfaces2005，44，23： | 1 |
| 4 | Global Atrativitity of a Generalized Lotka-Volterra Competition Model 显示文摘 | Chen Fengde Yu Mingchen Guo Shangjiang Li Zhong | 2010 | Differ Equ Dyn Syst2010，18，3： | 1 |
| 5 | Non-small cell lung cancers(NSCLCs)oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors显示文摘With the continuous in-depth study of the interaction mechanism between viruses and hosts,the virus has become a promising tool in cancer treatment.In fact,many oncolytic viruses with selectivity and effectiveness have been used in cancer therapy.Human enterovirus is one of the most convenient sources to generate oncolytic viruses,however,the high seroprevalence of some enteroviruses limits its application which urges to exploit more oncolytic enteroviruses. | Bopei Cui Lifang Song Qian Wang Kelei Li Qian He Xing Wu Fan Gao Mingchen Liu Chaoqiang An Qiushuang Gao Chaoying Hu Xiaotian Hao Fangyu Dong Jiuyue Zhou Dong Liu Ziyang Song Xujia Yan Jialu Zhang Yu Bai Qunying Mao Xiaoming Yang Zhenglun Liang | 2023 | Signal Transduction and Targeted Therapy2023，8，10： | 0 |
| 6 | Standardized neutralization antibody analytical procedure for clinical samples based on the AQbD concept显示文摘Dear Editor,Vaccination is an effective strategy for controlling the COVID-19 pandemic and reducing the number of cases of hospitalization and deaths.1 Neutralizing antibody(Ntab)is one of the key indicators for evaluating the effectiveness of COVID-19 vaccines.2 Over 40 COVID-19 vaccines have been approved for emergency use,marketing,or marketing with conditions,and the available Ntab data from clinical trials have been published. | Jianyang Liu Yu Bai Mingchen Liu Dejiang Tan Jing Li Zhongfang Wang Zhenglun Liang Miao Xu Junzhi Wang Qunying Mao | 2023 | Signal Transduction and Targeted Therapy2023，8，5： | 0 |
| 7 | Clinical Observation and Network Pharmacology Study on Analgesic Effect of Qianghuo Chushi Decoction on Fasciitis显示文摘[Objectives]To observe the clinical analgesic effect of Qianghuo Chushi Decoction(QHCSD)on patients with fasciitis,and explore its possible molecular mechanism based on network pharmacology.[Methods]120 enrolled patients were randomly divided into experimental group and control group,and were separately treated with QHCSD formula granules and Diclofenac Sodium Enteric-coated Tablets for 4 weeks.The patient’s pain visual analogue scale(VAS)was used as the curative effect indicator.The molecular action mechanism of QHCSD was predicted based on network pharmacology,the active components of QHCSD were screened using TCMSP database,potential targets were predicted by PharmMapper server,compound-target network and protein interaction network were constructed,and GO-based enrichment analysis and KEGG-based biological pathway enrichment analysis were performed.[Results]After treatment,the pain scores in each group were significantly lower than those before treatment(P<0.01),the score of the experimental group was significantly lower than that of the control group(P<0.01),and the total effective rate of the experimental group was 83.33%,which was significantly higher than that of the control group(78.33%,P<0.05).Based on 108 active components in QHCSD,a compound-target network was constructed.The PPI network contained 155 nodes and 527 interaction relationships,and key nodes included FOS,ESR1,NCOA1,RELA,EGFR,MAPK8,IL-6,etc.The GO pathway mainly involved steroid hormone and its receptor activity,RNA polymerase II transcriptional regulator binding,nuclear receptor activity,protein heterodimerization activity and other pathways.KEGG metabolic pathways included PI3 K-Akt signaling pathway,Kaposi’s sarcoma-associated herpesvirus(KSHV)infection and other pathways.[Conclusions]QHCSD has a significant analgesic effect on fasciitis,and the PI3 K-Akt signaling pathway may be the key pathway for its analgesic effect. | Mingchen CAO Lei DONG Chuan WANG Wenjing LI Xinxin WEI Shasha ZHANG Hongxia YU Cheng CHENG Xue YANG | 2022 | Medicinal Plant2022，13，5： | 0 |
| 8 | Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape显示文摘Chimeric antigen receptor(CAR)T-cell therapy has demonstrated clinical response in treating both hematologic malignancies and solid tumors.Although instances of rapid tumor remissions have been observed in animal models and clinical trials,tumor relapses occur with multiple therapeutic resistance mechanisms.Furthermore,while the mechanisms underlying the long-term therapeutic resistance are well-known,short-term adaptation remains less understood.However,more views shed light on short-term adaptation and hold that it provides an opportunity window for long-term resistance.In this study,we explore a previously unreported mechanism in which tumor cells employ trogocytosis to acquire CAR molecules from CAR-T cells,a reversal of previously documented processes.This mechanism results in the depletion of CAR molecules and subsequent CAR-T cell dysfunction,also leading to short-term antigen loss and antigen masking.Such type of intercellular communication is independent of CAR downstream signaling,CAR-T cell condition,target antigen,and tumor cell type.However,it is mainly dependent on antigen density and CAR sensitivity,and is associated with tumor cell cholesterol metabolism.Partial mitigation of this trogocytosis-induced CAR molecule transfer can be achieved by adaptively administering CAR-T cells with antigen density-individualized CAR sensitivities.Together,our study reveals a dynamic process of CAR molecule transfer and refining the framework of clinical CAR-T therapy for solid tumors. | You Zhai Yicong Du Guanzhang Li Mingchen Yu Huimin Hu Changqing Pan Di Wang Zhongfang Shi Xu Yan Xuesong Li Tao Jiang Wei Zhang | 2024 | Signal Transduction and Targeted Therapy2024，9，1： | 0 |
| 9 | Advances in Research of Mechanism of Herb-Drug Interactions显示文摘With the concurrent consumption of herbal medicines and conventional drugs,herb-drug interactions(HDIs)have become the most important clinical consequence of this practice.A general overview and the significance of pharmacokinetic and pharmacodynamic HDIs are provided,detailing basic mechanism,especially the metabolic enzymes and drug transporters,such as CYP450 and P-gp. | Mingchen CAO Chuan WANG Zhiwei YANG Zenan ZHANG Wenxiao WANG Hongxia YU Shasha ZHANG Cheng CHENG Wei REN | 2023 | Medicinal Plant2023，14，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员